Plain-English translation of NCT07243405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Lunair Alpha System, an implanted device that uses nerve stimulation to help treat moderate to severe sleep apnea. Sleep apnea is a condition where your breathing stops and starts repeatedly during sleep, which can be serious if left untreated. The study aims to determine if this device is safe and effective for people who have not had success with other available sleep apnea treatments.
Many people with sleep apnea struggle with or cannot use standard treatments like CPAP machines. This trial exists to see if this new nerve stimulation device could offer an alternative that works better for patients who need other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo the surgical implantation of the Lunair Alpha System device. After implantation, you would participate in follow-up visits and sleep studies to monitor how well the device works and whether it is safe. The study will track your breathing and sleep quality over time to evaluate whether this treatment helps reduce your sleep apnea symptoms.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Panama
Sponsor
Lunair Medical
Enrollment target
~45 participants
Started
July 2025
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kris VP, Clinical Operations
Lunair Medical
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.